Er wordt gejaagd op MdxHealth..
With this buyout, if it takes place, Illumina will gain control over Cologuard - the sole marketable product that Exact Sciences currently offers. Notably, Cologuard is the first-of-its kind and only FDA approved non-invasive screening test that uses stool DNA technology to detect colorectal cancer. Furthermore, Exact Sciences is currently collaborating with the Mayo Foundation for Medical Education and Research to develop DNA tests involving screening of lung, pancreatic and esophageal cancers, going ahead.
No doubt this acquisition will improve Illumina's oncology business, with the current market opportunity for Cologuard estimated to be $4 billion. Moreover, to establish itself more firmly in the cancer therapeutic space, earlier this yearIllumina created a new company, Grail, with a special focus on early cancer detection through a blood-based biopsy test and it aims to reduce global cancer mortality.